Novo Nordisk A/S (NVO)’s Pipeline Could Fuel Future Growth
We recently published a list of 10 Best Foreign Stocks To Buy Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other best foreign stocks to buy now.
The close of 2024 is resulting in a much needed paradigm shift for US and global equities. Ever since the coronavirus pandemic disrupted our way of living in 2020, investors have had to deal with one setback or another. While the immediate effect of the pandemic equities saw technology stocks soar, other sectors, such as energy and travel didn’t. Then, inflation rose in 2022 forcing central banks worldwide to rapidly hike interest rates, which naturally made equities much less attractive than before.
Since then, rates have been high in Europe and the US as well as in the developing world. However, with the European Central Bank’s (ECB) and Bank of England’s (BOE) latest rate cut decision, things appear to be changing. The ECB got the ball rolling in June after it cut interest rates by 25 basis points and then followed up with another 25 point cut in September. These decisions have been influenced to some extent by economic growth concerns. During the press conference after she announced the rate cuts, ECB President Christine Lagarde commented that while her organization had initially expected European economic growth to pick up, this hadn’t been the case.
As per Lagarde, “We have revised downwards the outlook for growth, because the consumption that we had anticipated for now, essentially, because net income has begun to increase, inflation has gone down significantly and we were expecting consumption to pick up, has not picked up. And I think that we will be looking at that carefully when we produce our next growth and GDP numbers.” During Q2 2024, the EU and broader Euro area’s GDP grew sequentially by 0.3%, which was similar to the Q1 figures. On an annual basis, the EU’s GDP marked a 0.8% growth while the Euro area’s growth was 0.6%. Lagarde’s comments were accompanied by the ECB’s updated growth estimates for 2024, 2025, and 2026. While it had expected these to sit at 0.9%, 1.4%, and 1.6%, respectively, the updated estimates reduced all of these by 0.1 percentage point.
With the EU’s economic performance, one country’s under performance is relevant for the broader area as well as an analysis of foreign or exUSA economies. This country is Europe’s largest economy, Germany. The German economy was 2023’s worst performer among major economies as it contracted by 0.3%. In Q2, the GDP contracted by 0.1% sequentially and missed analyst estimates of 0.1%. This slowdown came at a time when inflation jumped by 2.6% in July and accelerated by 0.1 percentage point over June. The economic uncertainty has also affected German investors, as data from the ZEW economic research institute’s economic sentiment index shows that the index fell to a whopping 3.6 points from an earlier 19.2 points. Analysts had expected it to sit at 17 points. Additionally, investor perceptions of the economy fell to levels last seen just as the coronavirus had started to wreak havoc in May 2020 and sat at -84.5.
Germany is struggling because the aftermath of the Russian invasion of Ukraine has cut its supply of cheap Russian gas. While this has increased costs, on the demand side, Germany is suffering from a weak Chinese economy. Data from the Federal Statistical Office shows that Germany’s exports to China in May sat at €7.5 billion for a 14% annual drop. Between January to May, the exports were €40.3 billion, for a 10%+ drop over 2022. With German firms such as LVMH experiencing a 14% Chinese sales drop in Q2 and Swatch witnessing a 30% drop in H1, it’s clear that Chinese consumers are in no mood for discretionary spending.
This has also led to Goldman recommending that investors sell European stocks with Chinese exposure as it is worried about its basket of European stocks. As per the bank, while “a great deal of earnings downgrades have already occurred year-to-date for our luxury basket, we worry that more could take place.” It adds that “Also, the valuation premium of the basket has deflated, but remains on the high side of its history.”
Pessimism about China is evident in the data as well. During Q2, the economy grew by 4.7%, with retail sales whimpering through a 2% growth rate. This was the slowest since December 2022, when the Zero COVID lock downs were still making their impact across the country. In the aftermath of the disappointing data from the world’s second largest economy, Goldman and Citi, which had earlier expected the Chinese economy to grow by 4.9% and 4.8%, slashed their estimates to 4.7%. Goldman commented “We believe the risk that China will miss the ‘around 5%’ full-year GDP growth target is on the rise, and thus the urgency for more demand-side easing measures is also increasing,” while Citi stated, “We believe fiscal policy needs to step up to so as to break the austerity trap and timely deploy growth support.”
Yet, while Germany and China have struggled, the world’s largest economy America has thrived. US GDP grew by 3.1% annually in Q2, lending credence to the argument of American exceptionalism. On a quarterly basis, it was up by 0.7%, despite the fact that interest rates remain at a 24 year high. This growth has created ample room for the Federal Reserve to keep rates high, and now, most expect that an interest rate cut is incoming. Due to America’s dominant role in global economic affairs, the Fed’s decisions have a global impact. For European stocks, it meant that the day before the rate cut decision, the index tracking Europe’s top 600 stocks gained 0.5% while the British stock market jumped by 0.7%.
Our Methodology
To make our list of the best foreign stocks to buy, we ranked the 40 most valuable exUS stocks in terms of market capitalization by the number of hedge funds that had bought their shares in Q2 2024. Out of these, the top stocks were chosen. Care was taken to ensure that stocks that were founded in America but are headquartered in Ireland or other jurisdictions were eliminated.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products.
Novo Nordisk A/S (NYSE:NVO)
Number of Hedge Fund Holders In Q2 2024: 67
Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that is one of the largest of its kind in the world. Yet, it is a highly specialized firm that offers products primarily for diabetes, weight loss, and rare diseases. This specialization coupled with Novo Nordisk A/S (NYSE:NVO)’s massive financial resources as highlighted by its cash and equivalents of $62.6 billion means that the firm can establish key footholds in some of the fastest growing healthcare markets. The stock is up by 44% over the past year primarily on the back of Novo Nordisk A/S (NYSE:NVO)’s Wegovy weight loss drug. Additionally, since it has considerable experience with diabetes drugs, that are precursors to weight loss treatments, the firm has been able to keep up with researching new treatments. Novo Nordisk A/S (NYSE:NVO) currently has CagriSema and amycretin in the pipeline as new weight loss treatments, and it could see additional tailwinds if CagriSema’s phase three results yield favorable results. It is also looking to use its weight loss formula semaglutide to treat Alzheimer’s.
Polen Capital mentioned Novo Nordisk A/S (NYSE:NVO) in its Q4 2023 investor letter. Here is what the firm said:
“As we discussed in last quarter’s commentary, Novo Nordisk is a newer addition to the strategy. Over the fourth quarter, we continued to build the position to an average weight. As a reminder, Novo Nordisk is a global pharmaceutical company based in Denmark and has long been the leader in developing insulin for diabetes patients. In recent years, the company’s innovation into GLP-1 drugs has been shown not only to help diabetics control blood sugar levels but also to have significant efficacy in weight loss. Obesity has become a global epidemic, creating materially negative knock-on effects for humans that range from an increase in cardiovascular events and, thus, higher mortality to a lower general quality of life. We believe that, over time, payors will recognize the value of these obesity treatments to both patients and the overall healthcare system.”
Overall NVO ranks 5th on our list of best foreign stocks to buy now. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.